Finanzen von Jasper Therapeutics Inc (JSPR)JSPRJasper Therapeutics Inc

Evaluating the bottom line, Jasper Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -255.05%, provide a clear picture of how effectively JSPR converts its operational activities into shareholder value.

In the context of the broader market, JSPR competes directly with industry leaders such as ENLV and MRKR. With a market capitalization of $23.28M, it holds a significant position in the sector. When comparing efficiency, JSPR's gross margin of N/A stands against ENLV's N/A and MRKR's N/A. Such benchmarking helps identify whether Jasper Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Jasper reported a net loss of $2.8 million in Q2 2026, an increase from a loss of $0.03 million in the same quarter last year, reflecting financial pressure. The company has a current ratio of 1.47, which is declining, indicating potential liquidity concerns.